Physician profile
Andrejs Strauss
NPI 1356343552
$1,513.91
in general payments reported to CMS, 2019-2025
10 companies · $851 in 2025
The $851 reported for 2025 was more than what 81% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2021: $90.00 · 2022: $116 · 2023: $93.84 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $944.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $279.32 | 2019-2021 | |
| Janssen Biotech, INC. | $249.26 | 2019-2025 | Carvykti, Rybrevant, Darzalex |
| Bayer Healthcare Pharmaceuticals INC. | $248.40 | 2025 | |
| Eisai INC. | $144.07 | 2019-2025 | |
| Beone Medicines USA, INC. | $126.00 | 2025 | Tevimbra |
| Daiichi Sankyo INC. | $122.00 | 2025 | Enhertu |
| Lilly USA, LLC | $115.50 | 2022 | |
| Boston Scientific Corporation | $108.58 | 2019 | |
| Exelixis INC. | $104.73 | 2025 | Cabometyx |
| Seagen INC. | $16.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrejs Strauss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.